IE53029B1 - Pharmaceutical preparations containing d-homo-4, 17-androstadien-3-one - Google Patents
Pharmaceutical preparations containing d-homo-4, 17-androstadien-3-oneInfo
- Publication number
- IE53029B1 IE53029B1 IE848/82A IE84882A IE53029B1 IE 53029 B1 IE53029 B1 IE 53029B1 IE 848/82 A IE848/82 A IE 848/82A IE 84882 A IE84882 A IE 84882A IE 53029 B1 IE53029 B1 IE 53029B1
- Authority
- IE
- Ireland
- Prior art keywords
- androstadien
- homo
- pharmaceutical preparations
- preparations containing
- treated
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 230000000699 topical effect Effects 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 238000006317 isomerization reaction Methods 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000004132 lipogenesis Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- HNDHDMOSWUAEAW-VMXHOPILSA-N androstadienone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC2=C1 HNDHDMOSWUAEAW-VMXHOPILSA-N 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004728 ear cartilage Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Obesity (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Coating Apparatus (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813115995 DE3115995A1 (de) | 1981-04-13 | 1981-04-13 | D-homo-4,17-androstadien-3-on, verfahren zu seiner herstellung und diese verbindung enthaltende pharmazeutische praeparate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE820848L IE820848L (en) | 1982-10-13 |
| IE53029B1 true IE53029B1 (en) | 1988-05-11 |
Family
ID=6130598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE848/82A IE53029B1 (en) | 1981-04-13 | 1982-04-08 | Pharmaceutical preparations containing d-homo-4, 17-androstadien-3-one |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4456620A (OSRAM) |
| EP (1) | EP0062904B1 (OSRAM) |
| JP (1) | JPS57179200A (OSRAM) |
| AT (1) | ATE17857T1 (OSRAM) |
| DE (2) | DE3115995A1 (OSRAM) |
| DK (1) | DK164082A (OSRAM) |
| ES (1) | ES511254A0 (OSRAM) |
| GB (1) | GB2099824A (OSRAM) |
| GR (1) | GR75469B (OSRAM) |
| IE (1) | IE53029B1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5110801A (en) * | 1984-08-13 | 1992-05-05 | Leveen Harry H | Treatment of acne |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB556734A (en) * | 1940-01-17 | 1943-10-20 | Chem Ind Basel | Manufacture of compounds of the ring-d-homo-steroid series |
| DE1493183C3 (de) * | 1965-12-11 | 1975-04-10 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | D-Homosteroide, Verfahren zu ihrer Herstellung und diese enthaltende Mittel |
| US3984476A (en) * | 1974-10-18 | 1976-10-05 | Andor Furst | D-homo-19-norsteroids |
| GB1550343A (en) * | 1975-07-16 | 1979-08-15 | Gist Brocades Nv | Androstane derivatives |
-
1981
- 1981-04-13 DE DE19813115995 patent/DE3115995A1/de not_active Withdrawn
-
1982
- 1982-04-07 ES ES511254A patent/ES511254A0/es active Granted
- 1982-04-08 DE DE8282103031T patent/DE3268919D1/de not_active Expired
- 1982-04-08 AT AT82103031T patent/ATE17857T1/de not_active IP Right Cessation
- 1982-04-08 EP EP82103031A patent/EP0062904B1/de not_active Expired
- 1982-04-08 IE IE848/82A patent/IE53029B1/en unknown
- 1982-04-08 GB GB8210401A patent/GB2099824A/en not_active Withdrawn
- 1982-04-09 JP JP57058363A patent/JPS57179200A/ja active Granted
- 1982-04-13 GR GR67914A patent/GR75469B/el unknown
- 1982-04-13 DK DK164082A patent/DK164082A/da not_active IP Right Cessation
- 1982-04-13 US US06/367,866 patent/US4456620A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK164082A (da) | 1982-10-14 |
| US4456620A (en) | 1984-06-26 |
| GB2099824A (en) | 1982-12-15 |
| JPH0212237B2 (OSRAM) | 1990-03-19 |
| GR75469B (OSRAM) | 1984-07-23 |
| EP0062904B1 (de) | 1986-02-05 |
| ATE17857T1 (de) | 1986-02-15 |
| ES8303451A1 (es) | 1983-02-16 |
| DE3268919D1 (en) | 1986-03-20 |
| EP0062904A1 (de) | 1982-10-20 |
| IE820848L (en) | 1982-10-13 |
| JPS57179200A (en) | 1982-11-04 |
| ES511254A0 (es) | 1983-02-16 |
| DE3115995A1 (de) | 1982-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Horst et al. | Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man | |
| CA1146070A (en) | Topical triethylenetetramine-containing pharmaceutical compositions and methods of use | |
| ATE128362T1 (de) | Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen. | |
| Pashko et al. | Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids | |
| Fluharty et al. | Sulfoglycerogalactolipid from rat testis: a substrate for pure human arylsulfatase A | |
| Vickers et al. | Carnitine and glucuronic acid conjugates of pivalic acid | |
| Touitou et al. | Changes in corticosteroid synthesis of the human adrenal cortex in vitro, induced by treatment with o, p'-DDD for Cushing's syndrome: Evidence for the sites of action of the drug | |
| Levin et al. | Inhibitory effect of phenobarbital or chlordane pretreatment on the androgen-induced increase in seminal vesicle weight in the rat | |
| Brem et al. | Effect of carbenoxolone on glucocorticoid metabolism and Na transport in toad bladder | |
| Plante et al. | Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice | |
| Morris et al. | The 11 beta-OHSD inhibitor, carbenoxolone, enhances Na retention by aldosterone and 11-deoxycorticosterone | |
| IE53029B1 (en) | Pharmaceutical preparations containing d-homo-4, 17-androstadien-3-one | |
| US3886268A (en) | Iodophor-steroid compound pharmaceutical compositions | |
| US4670427A (en) | 1α,2α-methylene-6-methylene- and 6α-methylpregnenes, their preparation and pharmaceutical use | |
| MARTIN | Fecal metabolites of testosterone-4-14C in the bovine male castrate | |
| Ward et al. | Properties of the ultraviolet-absorbing lipids produced by rat adrenals in vitro | |
| Mahler | BUTYRYL CoA-DEHYDROGENASE, A CUPRO-FLAVO-PROTEIN | |
| Demers et al. | The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer | |
| Tindall et al. | Estradiol-17 β inhibition of androgen uptake, metabolism and binding in epididymis of adult male rats in vivo: A comparison with cyproterone acetate | |
| US4673673A (en) | 17α-alkyl-17β-hydroxy-1α-methyl-4-androsten-3-ones, their production and use pharmaceutically | |
| IE42308B1 (en) | 16, 16-disubstituted steroids of the androstene series | |
| CA1069437A (en) | Steroidal erythropoietic agents and therapeutic compositions and methods | |
| US3228837A (en) | Oral anabolic composition and method of use | |
| Mathur et al. | Steroid estrogen conjugates of hen's urine: Formation in vivo of steroid estrogen monosulphates and disulphates from injected estradiol-17β | |
| Wing et al. | Differential responses of sex steroid target tissues of rats treated with 4-hydroxyandrostenedione |